New options for ovarian cancer and NSCLC

The PARP inhibitor olaparib has been approved by the TGA for use in a subset of patients with ovarian cancer, while nivolumab is now authorised for certain patients with NSCLC.

Associate Professor Clare Scott of the Walter and Eliza Hall Institute says that the oral PARP inhibitor treatment option is “a very good one for patients with BRCA1 and BRCA2-associated ovarian cancer.”